research Дослідження ПРОСПЕКТ IV (ПРОСтамол: ПЕрспективи Комбінованої Терапії) у хворих на доброякісну гіперплазію передміхурової залози
"Flosin – Prostamol Uno" effectively manages BPH symptoms with fewer side effects.
Search
for
Sort by
Research
870-900 / 1000+ resultsresearch Updated Integrated Efficacy Analysis of Ritlecitinib Up to 3 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is effective long-term for treating alopecia areata in teens.
research Metabolic effects of 5α-reductase inhibition in humans
Dutasteride may reduce insulin sensitivity and increase body fat.
research 5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review
5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
research 708 Promotion of hair growth in alopecia areata by topical treatment of HDAC inhibitors
HDAC inhibitors, like Vorinostat and Entinostat, can help regrow hair in alopecia areata.
research Observation and consideration on using of JAKi in clinical trials in times of COVID ‐19
Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.
research 600 Impact of baricitinib on work productivity and indirect costs in adult patients with atopic dermatitis: A meta-analysis of clinical trials
Baricitinib at 2mg and 4mg doses improved work productivity and reduced costs for adults with atopic dermatitis.
research Dutasteride: A Review of its Use in the Management of Prostate Disorders
Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.
research Preparation and Characterization of Solution-Processed Nanocrystalline p-Type CuAlO2 Thin-Film Transistors
Turmeric may improve knee osteoarthritis, depression, and metabolic syndrome, but evidence is weak.
research Stewardship of Medication Errors in A Developing Country’s Scenario: A Clinical Pharmacist’s Role
Clinical pharmacists are crucial in improving patient safety by reporting medication errors in hospitals.
research The Relationship Between Socio Economic Status and Traumatic Brain Injuries for Pediatric Populations
Kids from areas with more high school dropouts have higher rates of brain injuries.
research Additional Benefit Scoring During Health Technology Assessment in Germany - Its Drivers and Impact on Pricing and Discount for Orphan Drugs
Orphan drug benefit scores in Germany are influenced by phase III data and lack of alternatives, but not linked to price or discounts.
research Dutasteride: a guide to its use as monotherapy in benign prostatic hyperplasia
Dutasteride effectively treats benign prostatic hyperplasia, improving symptoms and quality of life.
research Trends in the prescribing pattern of spironolactone for acne and hidradenitis suppurativa in adolescents
Doctors are prescribing spironolactone more often to treat acne and skin conditions in teenagers, and it seems safe and well-tolerated.
research ▼ Strontium ranelate discontinued
Strontium ranelate is no longer available for treatment.
research Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique
Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.
research Low-dose (2.5 mg/day) finasteride treatment in hirsutism
Low-dose finasteride effectively reduces hirsutism without serious side-effects.
research Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
research 5PSQ-117 Effectiveness of baricitinib in alopecia areata
Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.
research Spironolactone in dermatology: uses in acne and beyond
Spironolactone is a low-cost, effective, and generally safe treatment for various skin conditions related to hormones.
research Finasteride for recurrent priapism in children and adolescents: a report on 5 cases
Finasteride effectively and safely treats recurrent priapism in children and adolescents with sickle cell disease.
research Intermittent Use of Testosterone Inactivating Pharmaceuticals Using Finasteride Prolongs the Time Off Period
Using finasteride with TIP extends time off period for prostate cancer patients.
research Sun behaviors and quality of life after first cutaneous melanoma diagnosis
Finasteride use for hair loss is linked to an increased risk of suicidal thoughts and a higher risk of suicide.
research In Silico Screening of DrugBank Compounds as Potential Inhibitors for Human Steroid 5α-Reductase 2 for Androgen-Related Diseases
Stiripentol shows promise as a potential treatment for androgen-related diseases but needs more testing.
research Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study
Men taking dutasteride or finasteride have a slightly higher risk of developing type 2 diabetes.
research Experimental and Finite Element Analysis of a Residual Hair Keratin‐based Hydrogel with Calcium for Atorvastatin Sequestration, Release, and In Vitro Activity
Keratin-based hydrogels with calcium are effective for delivering anti-fibrotic drugs.
research Patient Profile and Treatment Characteristics of Adults and Adolescents Prescribed Ritlecitinib for Alopecia Areata in the USA
Ritlecitinib provides new treatment options for diverse alopecia areata patients.
research 15809 Spironolactone use does not increase the risk of estrogen-dependent cancer recurrence: A retrospective analysis
Taking vitamin C and vitamin E twice a day can help prevent sunburn and DNA damage from UVB exposure.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research Long-Term Efficacy and Complete Scalp Hair Regrowth in Patients With Alopecia Areata Receiving Ritlecitinib 50 mg QD Up to 3 Years in the ALLEGRO Clinical Trial Program
Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.